Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy

RD Guber, V Takyar, A Kokkinis, DA Fox, H Alao… - Neurology, 2017 - AAN Enterprises
RD Guber, V Takyar, A Kokkinis, DA Fox, H Alao, I Kats, D Bakar, AT Remaley, SM Hewitt
Neurology, 2017AAN Enterprises
Objective: To determine the prevalence and features of fatty liver disease in spinal and
bulbar muscular atrophy (SBMA). Methods: Two groups of participants with SBMA were
evaluated. In the first group, 22 participants with SBMA underwent laboratory analysis and
liver imaging. In the second group, 14 participants with SBMA were compared to 13 female
carriers and 23 controls. Liver biopsies were done in 4 participants with SBMA. Results:
Evidence of fatty liver disease was detected by magnetic resonance spectroscopy in all …
Objective
To determine the prevalence and features of fatty liver disease in spinal and bulbar muscular atrophy (SBMA).
Methods
Two groups of participants with SBMA were evaluated. In the first group, 22 participants with SBMA underwent laboratory analysis and liver imaging. In the second group, 14 participants with SBMA were compared to 13 female carriers and 23 controls. Liver biopsies were done in 4 participants with SBMA.
Results
Evidence of fatty liver disease was detected by magnetic resonance spectroscopy in all participants with SBMA in the first group, with an average dome intrahepatic triacylglycerol of 27% (range 6%–66%, ref ≤5.5%). Liver dome magnetic resonance spectroscopy measurements were significantly increased in participants with SBMA in the second group relative to age- and sex-matched controls, with average disease and male control measurements of 17% and 3%, respectively. Liver biopsies were consistent with simple steatosis in 2 participants and nonalcoholic steatohepatitis in 2 others.
Conclusions
We observed evidence of nonalcoholic liver disease in nearly all of the participants with SBMA evaluated. These observations expand the phenotypic spectrum of the disease and provide a potential biomarker that can be monitored in future studies.
American Academy of Neurology